Overview

Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy

Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
This study is to examine which dose of YPEG-rhG-CSF, once-per-cycle, has similar efficacy and safety, comparing to PEG-rhG-CSF, once-per-cycle, in chemotherapy-induced neutropenia
Phase:
Phase 2
Details
Lead Sponsor:
Xiamen Amoytop Biotech Co., Ltd.